Patient derived organoids as a platform for inferring treatment response in pancreatic cancer patients

源自患者的类器官作为推断胰腺癌患者治疗反应的平台

• 批准号: 451144
• 负责人: Gallinger Steven
• 金额: $ 71.06万
• 依托单位: Ontario Institute for Cancer Research (Toronto, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-09-01 至 2026-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=451144&lang=en
• 关键词: Better Treatment Selection For Patients; Chemosensitivity And Resistance; Genomic And Transcriptomic Sequencing; Improving Survival And Patient Outcome; Models Of Patient Response; Pancreatic Cancer; Patient Derived Organoids; Pharmacotyping; Targeted Can

Pancreatic cancer is one of the deadliest cancers. Most patients are diagnosed when the tumour is too big or has spread to other organs, so it can no longer be removed by surgery. The only alternative is to treat the tumour with chemotherapy. To date, the

胰腺癌是最致命的癌症之一。大多数患者是在肿瘤太大或扩散到其他器官时被诊断出来的，因此不能再通过手术切除。唯一的选择是用化疗来治疗肿瘤。到目前为止，